Antibacterial Efficacy of Inhalable Levofloxacin-Loaded Polymeric Nanoparticles Against E. coli Biofilm Cells: The Effect of Antibiotic Release Profile

Cheow, Wean Sin; Chang, Matthew Wook; Hadinoto, Kunn

doi:10.1007/s11095-010-0142-6

Cited by 104 publications

(54 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[107] Growth inhibition of S. epidermidis biofilms due to application of triclosan-containing DPPC:PI, DPPG:PI or DPPC liposomes was evaluated and linked to the drug to lipid molar ratio's. [75] All the liposomes tested showed a certain degree of inhibition of the bacterial growth, but only for low drug to [96] lipid ratios an advantage of liposomal delivery was seen. The targeting to the biofilm was less pronounced for high drug/lipid ratios, which could explain these results.…”

Section: Non-specific Targetingmentioning

confidence: 99%

“…This is needed to prevent the increase in antibiotic tolerance of the surviving biofilm cells. [96] In a time-kill biofilm susceptibility test which was conducted over five days, in vivo conditions of drug removal were simulated by diluting the solution twofold every 24 hours. This test takes into account the effect of biofilm age and could reveal if the susceptibility of the biofilm is changed during a prolonged antibiotic exposure.…”

Section: Controlled Releasementioning

confidence: 99%

See 1 more Smart Citation

Lipid and polymer nanoparticles for drug delivery to bacterial biofilms

Forier

Raemdonck

Smedt

et al. 2014

Journal of Controlled Release

372

320

View full text Add to dashboard Cite

Biofilms are matrix-enclosed communities of bacteria that show increased antibiotic resistance and the capability to evade the immune system. They can cause recalcitrant infections which cannot be cured with classical antibiotic therapy. Drug delivery by lipid or polymer nanoparticles is considered a promising strategy for overcoming biofilm resistance. These particles are able to improve the delivery of antibiotics to the bacterial cells, thereby increasing the efficacy of the treatment. In this review we give an overview of the types of polymer and lipid nanoparticles that have been developed for this purpose. The antimicrobial activity of nanoparticle encapsulated antibiotics compared to the activity of the free antibiotic is discussed in detail. In addition, targeting and triggered drug release strategies to further improve the antimicrobial activity are reviewed. Finally, ample attention is given to advanced microscopy methods that shed light on the behavior of nanoparticles inside biofilms, allowing further optimization of the nanoformulations. Lipid and polymer nanoparticles were found to increase the antimicrobial efficacy in many cases. Strategies such as the use of fusogenic liposomes, targeting of the nanoparticles and triggered release of the antimicrobial agent ensured the delivery of the antimicrobial agent in close proximity of the bacterial cells, maximizing the exposure of the biofilm to the antimicrobial agent. The majority of the discussed papers still present data on the in vitro anti-biofilm activity of nanoformulations, indicating that there is an urgent need for more in vivo studies in this field.

show abstract

Section: Non-specific Targetingmentioning

confidence: 99%

Section: Controlled Releasementioning

confidence: 99%

Lipid and polymer nanoparticles for drug delivery to bacterial biofilms

Forier

Raemdonck

Smedt

et al. 2014

Journal of Controlled Release

372

320

View full text Add to dashboard Cite

show abstract

“…Turos et al 14 showed polyacrylate nanoantibiotics associated with penicillin against methicillin-resistant S. aureus (MRSA), while, in this study, 64 µg⋅mL -1 minimum inhibitory concentration was also observed against MRSA. 14,15 Another study performed by Cheow et al 38 showed levofloxacin-loaded polymeric nanoparticles with 0.03 and 0.15 µg⋅mL -1 minimum inhibitory concentration and minimum biofilm inhibitory concentration against E. coli. 38 Furthermore, no hemolytic activities for tested samples were observed ( Figure S4), suggesting no cytotoxic activity against these cells, as previously observed by Nassar et al 28 These results demonstrated that nanoformulated clavanin here studied could be a suitable candidate for pharmaceutical applications.…”

Section: In Vitro Bioassaysmentioning

confidence: 99%

“…14,15 Another study performed by Cheow et al 38 showed levofloxacin-loaded polymeric nanoparticles with 0.03 and 0.15 µg⋅mL -1 minimum inhibitory concentration and minimum biofilm inhibitory concentration against E. coli. 38 Furthermore, no hemolytic activities for tested samples were observed ( Figure S4), suggesting no cytotoxic activity against these cells, as previously observed by Nassar et al 28 These results demonstrated that nanoformulated clavanin here studied could be a suitable candidate for pharmaceutical applications. This experiment associated with survival assays displayed in Figure 3 allows peptide viability to be inferred.…”

Section: In Vitro Bioassaysmentioning

confidence: 99%

See 1 more Smart Citation

Clavanin bacterial sepsis control using a novel methacrylate nanocarrier

Saúde¹,

Ombredane²,

Silva³

et al. 2014

IJN

View full text Add to dashboard Cite

Controlling human pathogenic bacteria is a worldwide problem due to increasing bacterial resistance. This has prompted a number of studies investigating peptides isolated from marine animals as a possible alternative for control of human pathogen infections. Clavanins are antimicrobial peptides isolated from the marine tunicate Styela clava , showing 23 amino acid residues in length, cationic properties, and also high bactericidal activity. In spite of clear benefits from the use of peptides, currently 95% of peptide properties have limited pharmaceutical applicability, such as low solubility and short half-life in the circulatory system. Here, nanobiotechnology was used to encapsulate clavanin A in order to develop nanoantibiotics against bacterial sepsis. Clavanin was nanostructured using EUDRAGIT ® L 100-55 and RS 30 D solution (3:1 w:w). Atomic force, scanning electron microscopy and dynamic light scattering showed nanoparticles ranging from 120 to 372 nm in diameter, with a zeta potential of -7.16 mV and a polydispersity index of 0.123. Encapsulation rate of 98% was assessed by reversed-phase chromatography. In vitro bioassays showed that the nanostructured clavanin was partially able to control development of Staphylococcus aureus , Klebsiella pneumoniae , and Pseudomonas aeruginosa . Furthermore, nanostructures did not show hemolytic activity. In vivo sepsis bioassays were performed using C57BL6 mice strain inoculated with a polymicrobial suspension. Assays led to 100% survival rate under sub-lethal sepsis assays and 40% under lethal sepsis assays in the presence of nanoformulated clavanin A until the seventh day of the experiment. Data here reported indicated that nanostructured clavanin A form shows improved antimicrobial activity and has the potential to be used to treat polymicrobial infections.

show abstract